Sensorion KOL Event on Cisplatin-induced ototoxicity
About The Event
The webinar will feature a presentation by Key Opinion Leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview on hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current treatment landscape, and the unmet medical need in adults.
Sensorion’s management team will also discuss the development of SENS-401 in cisplatin induced ototoxicity. A Q&A session will follow the formal presentations.
SENS-401 is a first-in-class drug candidate for the prevention and treatment of physical or chemical damage that leads to sensory hair cell loss including cisplatin induced ototoxicity.